Aglaia Therapeutics
French tech company | Builders Republic
About
Oncology biotech developing therapies to reverse resistance to targeted cancer treatments — enabling patients who no longer respond to approved targeted drugs to regain sensitivity, targeting best-in-class or first-in-class mechanisms. Backed by Advent France Biotechnology and Pierre Fabre.
Key facts
- Status
- Morte
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2021
- City
- VILLEJUIF
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 4.0 M€ raised since 2020
Funding rounds
- Seed — 2021
Investors
Notes
Renommée Ribonexus (2021).